Literature DB >> 17906676

Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis.

C Moro1, E Klimcakova, M Lafontan, M Berlan, J Galitzky.   

Abstract

BACKGROUND AND
PURPOSE: Atrial natriuretic peptide (ANP) stimulates lipolysis in human adipocyte through a cGMP signalling pathway, the regulation of which is poorly known. Since phosphodiesterases (PDE) and neutral endopeptidase (NEP) play a major role in the regulation of the biological effects of natriuretic peptides in the cardiovascular and renal systems, we investigated whether these mechanisms could regulate cGMP signalling and ANP-mediated lipolysis in human adipocytes. EXPERIMENTAL APPROACH: The presence of cGMP-specific PDE and NEP in differentiated pre-adipocytes and in mature adipocytes was evaluated by real-time qPCR and Western blot. The effect of non-selective and selective inhibition of these enzymes on ANP-mediated cGMP signalling and lipolysis was determined in isolated mature adipocytes. KEY
RESULTS: PDE-5A was expressed in both pre-adipocytes and adipocytes. PDE-5A mRNA and protein levels decreased as pre-adipocytes differentiated (10 days). PDE-5A is rapidly activated in response to ANP stimulation and lowers intracellular cGMP levels. Its selective inhibition by sildenafil partly prevented the decline in cGMP levels. However, no changes in baseline- and ANP-mediated lipolysis were observed under PDE-5 blockade using various inhibitors. In addition, NEP mRNA and protein levels gradually increased during the time-course of pre-adipocyte differentiation. Thiorphan, a selective NEP inhibitor, completely abolished NEP activity in human adipocyte membranes but did not modify ANP-mediated lipolysis. CONCLUSIONS AND IMPLICATIONS: Functional PDE-5A and NEP activities were present in human adipocytes, however these enzymes did not play a major role in the regulation of ANP-mediated lipolysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906676      PMCID: PMC2095109          DOI: 10.1038/sj.bjp.0707485

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases.

Authors:  S H Soderling; S J Bayuga; J A Beavo
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

Review 2.  Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.

Authors:  Lincoln R Potter; Sarah Abbey-Hosch; Deborah M Dickey
Journal:  Endocr Rev       Date:  2005-11-16       Impact factor: 19.871

3.  Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise.

Authors:  Cédric Moro; Jan Polak; Jindra Hejnova; Eva Klimcakova; François Crampes; Vladimir Stich; Max Lafontan; Michel Berlan
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-11-15       Impact factor: 4.310

Review 4.  Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome.

Authors:  Dominique Langin
Journal:  Pharmacol Res       Date:  2006-03-27       Impact factor: 7.658

5.  Differential regulation of atrial natriuretic peptide- and adrenergic receptor-dependent lipolytic pathways in human adipose tissue.

Authors:  Cédric Moro; Jan Polak; Blanka Richterova; Coralie Sengenès; Terezie Pelikanova; Jean Galitzky; Vladimir Stich; Max Lafontan; Michel Berlan
Journal:  Metabolism       Date:  2005-01       Impact factor: 8.694

Review 6.  Human fat cell lipolysis: biochemistry, regulation and clinical role.

Authors:  Peter Arner
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2005-12       Impact factor: 4.690

7.  Expression of natriuretic peptide receptors in human adipose and other tissues.

Authors:  R Sarzani; P Dessì-Fulgheri; V M Paci; E Espinosa; A Rappelli
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

8.  Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase.

Authors:  K Loughney; T R Hill; V A Florio; L Uher; G J Rosman; S L Wolda; B A Jones; M L Howard; L M McAllister-Lucas; W K Sonnenburg; S H Francis; J D Corbin; J A Beavo; K Ferguson
Journal:  Gene       Date:  1998-08-17       Impact factor: 3.688

9.  Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene.

Authors:  N Yanaka; J Kotera; A Ohtsuka; H Akatsuka; Y Imai; H Michibata; K Fujishige; E Kawai; S Takebayashi; K Okumura; K Omori
Journal:  Eur J Biochem       Date:  1998-07-15

10.  Down-regulation does not mediate natriuretic peptide-dependent desensitization of natriuretic peptide receptor (NPR)-A or NPR-B: guanylyl cyclase-linked natriuretic peptide receptors do not internalize.

Authors:  Danhua Fan; Paula M Bryan; Laura K Antos; Regine J Potthast; Lincoln R Potter
Journal:  Mol Pharmacol       Date:  2004-09-30       Impact factor: 4.436

View more
  14 in total

1.  Dendroaspis natriuretic peptide relaxes gastric antral circular smooth muscle of guinea-pig through the cGMP/cGMP-dependent protein kinase pathway.

Authors:  Chun-Yu Cai; Zheng-Xu Cai; Xin-Yi Gu; Lu-Juan Shan; Yong-Xiao Wang; Xue-Zhe Yin; Qing-Hui Qi; Hui-Shu Guo
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  Atrial natriuretic peptide regulates adipose tissue accumulation in adult atria.

Authors:  Nadine Suffee; Thomas Moore-Morris; Patrick Farahmand; Catherine Rücker-Martin; Gilles Dilanian; Magali Fradet; Daigo Sawaki; Geneviève Derumeaux; Pascal LePrince; Karine Clément; Isabelle Dugail; Michel Puceat; Stéphane N Hatem
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

3.  Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in human adipose tissue ex vivo.

Authors:  L De Toni; G Strapazzon; L Gianesello; N Caretta; C Pilon; A Bruttocao; C Foresta
Journal:  J Endocrinol Invest       Date:  2011-11       Impact factor: 4.256

4.  Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome.

Authors:  Cedric Moro; Magdalena Pasarica; Karen Elkind-Hirsch; Leanne M Redman
Journal:  J Clin Endocrinol Metab       Date:  2009-04-14       Impact factor: 5.958

5.  Impaired atrial natriuretic peptide-mediated lipolysis in obesity.

Authors:  M Rydén; J Bäckdahl; P Petrus; A Thorell; H Gao; M Coue; D Langin; C Moro; P Arner
Journal:  Int J Obes (Lond)       Date:  2015-10-26       Impact factor: 5.095

6.  Neprilysin, obesity and the metabolic syndrome.

Authors:  K F Standeven; K Hess; A M Carter; G I Rice; P A Cordell; A J Balmforth; B Lu; D J Scott; A J Turner; N M Hooper; P J Grant
Journal:  Int J Obes (Lond)       Date:  2010-11-02       Impact factor: 5.095

7.  Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue.

Authors:  Linda S Hoffmann; Jennifer Etzrodt; Lena Willkomm; Abhishek Sanyal; Ludger Scheja; Alexander W C Fischer; Johannes-Peter Stasch; Wilhelm Bloch; Andreas Friebe; Joerg Heeren; Alexander Pfeifer
Journal:  Nat Commun       Date:  2015-05-26       Impact factor: 14.919

8.  Targeting adipose tissue.

Authors:  Bodo Haas; Paul Schlinkert; Peter Mayer; Niels Eckstein
Journal:  Diabetol Metab Syndr       Date:  2012-10-27       Impact factor: 3.320

9.  Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity.

Authors:  B Omar; E Banke; M Ekelund; S Frederiksen; E Degerman
Journal:  Nutr Diabetes       Date:  2011-08-08       Impact factor: 5.097

Review 10.  A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure.

Authors:  Ryan P Ceddia; Sheila Collins
Journal:  Clin Sci (Lond)       Date:  2020-03-13       Impact factor: 6.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.